A detailed history of Candriam S.C.A. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 345,384 shares of KROS stock, worth $6.71 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
345,384
Previous 441,855 21.83%
Holding current value
$6.71 Million
Previous $20.2 Million 0.67%
% of portfolio
0.12%
Previous 0.12%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$41.68 - $58.07 $4.02 Million - $5.6 Million
-96,471 Reduced 21.83%
345,384 $20.1 Million
Q2 2024

Aug 05, 2024

SELL
$44.58 - $66.89 $9.37 Million - $14.1 Million
-210,144 Reduced 32.23%
441,855 $20.2 Million
Q1 2024

May 03, 2024

SELL
$41.26 - $70.48 $6.89 Million - $11.8 Million
-167,063 Reduced 20.4%
651,999 $43.2 Million
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $2.12 Million - $3.2 Million
78,001 Added 10.53%
819,062 $32.6 Million
Q3 2023

Nov 13, 2023

BUY
$31.57 - $43.02 $631,400 - $860,400
20,000 Added 2.77%
741,061 $23.6 Million
Q2 2023

Aug 08, 2023

SELL
$37.26 - $51.01 $894,090 - $1.22 Million
-23,996 Reduced 3.22%
721,061 $29 Million
Q1 2023

May 12, 2023

BUY
$41.44 - $59.32 $4.94 Million - $7.07 Million
119,143 Added 19.04%
745,057 $31.8 Million
Q4 2022

Feb 13, 2023

BUY
$39.45 - $51.77 $10.4 Million - $13.7 Million
264,125 Added 73.01%
625,914 $30.1 Million
Q2 2022

Aug 03, 2022

SELL
$26.03 - $67.04 $1.53 Million - $3.95 Million
-58,881 Reduced 14.0%
361,789 $10 Million
Q1 2022

May 13, 2022

BUY
$42.12 - $59.36 $7.57 Million - $10.7 Million
179,724 Added 74.59%
420,670 $22.9 Million
Q3 2021

Nov 09, 2021

BUY
$29.27 - $43.71 $4.08 Million - $6.1 Million
139,537 Added 137.6%
240,946 $9.53 Million
Q2 2021

Jul 20, 2021

BUY
$42.4 - $70.11 $4.3 Million - $7.11 Million
101,409 New
101,409 $4.31 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $500M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.